BioCentury
ARTICLE | Clinical News

Siamab Therapeutics preclinical data

October 10, 2016 7:00 AM UTC

In a mouse xenograft model of ovarian cancer, Siamab’s ST1 ADC composed of a sialosyl-Tn antigen (sTn) antibody and monomethyl auristatin E (MMAE) given every 7 days significantly reduced tumor volum...